Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 12/20 | 0.53 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6738003 | 0.86 | CMA1 (0.52) | CMA1ELANE | |
| SCHEMBL16923607 | 0.81 | ACE (0.51) | AGTR2ABCB1 | |
| SCHEMBL376159 | 0.81 | ABCB1 (0.52) | AGTR2ABCB1 | |
| SCHEMBL26604823 | 0.81 | ABCB1 (0.52) | AGTR2ABCB1 | |
| SCHEMBL708629 | 0.81 | ABCB1 (0.52) | AGTR2ABCB1 | |
| SCHEMBL7287734 | 0.81 | ABCB1 (0.52) | AGTR2ABCB1 | |
| SCHEMBL1448119 | 0.81 | ABCB1 (0.52) | AGTR2ABCB1 | |
| SCHEMBL949983 | 0.81 | ABCB1 (0.52) | AGTR2ABCB1 | |
| SCHEMBL3179881 | 0.81 | ABCB1 (0.52) | AGTR2ABCB1 | |
| SCHEMBL708628 | 0.81 | ABCB1 (0.52) | AGTR2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693072-B2 | Elastase inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-02-17 | — | — | US | disclosed |
| EP-0804465-B1 | NOVEL ELASTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2003-08-06 | — | — | EP | disclosed |
| US-20030096759-A1 | Novel elastase inhibitors | AVENTISUB II INC. | 2003-05-22 | — | — | US | disclosed |
| WO-1995033763-A1 | NOVEL ELASTASE INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096759-A1 | Novel elastase inhibitors | ELANE, SERPINB1, MMP8 | CMA1 75/4885AGTR2 1119/4885CAPN1 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.